


Medical / GP Referrals to Patient Blood Management

Anaemia (Hb <130g/dL in males / Hb <118g/dL in females)



Notes (see also: Iron deficiency. Pasricha S et al. The Lancet December 4th 2020)

- Iron deficiency anaemia is sometimes straight forward to identify but is often obscured by anaemia of chronic inflammation or other co-morbidities making diagnosis sometimes difficult. Sometimes the results will not fit neatly into one category and clinical discretion is advised.
- Check haematinics first, consider requesting reticulocytes and reticulocyte haemoglobin content (MCHr) which measures iron-restricted erythropoiesis and suggestive of iron-deficiency when <29pg. A blood film, CRP and iron studies (transferrin saturation (Tsat) of <20% is also suggestive of iron-deficiency) can help identify co-existing iron deficiency anaemia in cases of chronic inflammation. Consider also coeliac serology and IgA antibodies.
- Although ferritin can be useful (particularly if <15ug/L), there is little evidence to support specific cut-off values and it is often confounded by co-existing inflammation. There is no single gold-standard test to diagnose iron deficiency anaemia other than a bone-marrow biopsy which is invasive and rarely justified in this context. The above algorithm is a guideline to support clinical decision making and referral to patient blood management. **Of note is the advice on management of oral iron intolerance by suggesting alternate day, low to intermediate dosing: this improves absorption and reduces side-effects and should be strongly encouraged before referral for parenteral iron.**

Advice for GPs when Patient Encounters Intolerance to Oral Iron Replacement

Side effects of oral iron are common. It is therefore important to prescribe in a way that minimises these and avoids the need for referral for parenteral iron which is more invasive and costly. Clinicians are advised to consider the following measures to optimise tolerance of oral iron:

- intermediate or low dose ferrous sulphate e.g. 200mg o.d or b.d on alternate days: this is proven to reduce side effects and increases absorption.
- we also recommend iron is taken 30 minutes before a meal.
- advice to the patient on dietary improvement to optimise dietary iron intake.
- An alternative preparation such as ferrous gluconate or ferrous fumarate should be tried before abandoning oral iron.

NB. There is no benefit to enteric coated or modified release iron capsules. Some clinicians recommend giving oral iron with a source of ascorbic acid (vitamin C), either by taking it with orange juice or with a 500mg ascorbic acid tablet. This is based on the hypothesis that ascorbic acid may increase iron absorption. However some recently published studies show no major impact of lowering the pH on iron absorption and we are not aware of any high quality data to support this practice. Therefore we cannot make a strong recommendation on the addition of vitamin C to improve oral iron absorption.

If oral iron is ineffective in improving Hb, then referral to PBM remains appropriate.

References

1. Stoffel NU et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice daily split dosing in iron depleted women: two open label randomised controlled trials. *Lancet Haematol.* 2017; 4:e524-33
2. Iron deficiency. Pasricha S. *et al.* *The Lancet* December 4th 2020 [https://doi.org/10.1016/s0140-6736\(20\)32594-0](https://doi.org/10.1016/s0140-6736(20)32594-0)
3. Ponikowski P et al. Beneficial effects of long term intravenous therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. *Eur Heart J.* 2015; 36:657-68

Notes to Primary Care on Iron Deficiency in the Absence of Anaemia


The primary purpose of the Patient Blood Management Service is the management of patients suffering from anaemia with iron deficiency (IDA) in order to reduce patient exposure to blood transfusions and preserve blood stocks.

Whilst it is recognised that symptomatic iron deficiency in the absence of anaemia can benefit from replacement, it is strongly encouraged that every attempt is made to replace iron stores orally and address the cause in these circumstances^{2,3}.

The management of oral iron intolerance can be addressed by using oral iron on alternate days at a low (200mg FeSO₄) or intermediate dose – this improves absorption and reduces side-effects and should be tried before referral for parenteral iron (see references below).

Where capacity exists, cases of non-anaemic iron deficiency may be considered on a case-by-case basis by PBM, particularly where evidence for replacement is strongest; there is an established regular requirement for replacement (typically patients with inflammatory bowel disease or persistent menorrhagia pending intervention) and capacity within PBM exists.

Where PBM capacity does not allow for this, referrers are encouraged to use alternative facilities for infusional iron, such as within their own specialty departments, where iron infusions can be safely administered.

**NB**

- Ferritin is a good measure of storage iron but there are no good data to support specific cut-off values to rule out / in iron deficiency anaemia. Other values such as a low MCH, a mean reticulocyte haemoglobin concentration (MCHr) of <29 or, where iron studies are performed, a transferrin saturation of <20% can be helpful to indicate coexisting IDA in context of other causes of anaemia.
- In the context of inflammation (CRP >5) or cancer, ferritin levels can be elevated above 150 with functional iron deficiency (inaccessible iron stores). This can sometimes respond to IV iron and should be considered, particularly if MCHr <29 and other causes (such as B12 / folate deficiency) have been corrected / excluded.

Patient information leaflet available [here](#)

Contributors:

Dr David Tucker, Consultant Haematologist, RCHT

Dr Adam Forbes, Consultant Haematologist, RCHT

Dr Bridgitte Wesson, GP & Kernow RMS Haematology guideline lead

Dr Pietroni, Consultant Anaesthetist & Blood Transfusion Committee Chair

Review date: 15/03/2021

Next Review due 15/03/2022